Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma

Brain Research

Volumn 1188, Issue 1, 2008, Pages 173-181

  Patel, Rahima ^a   Shervington, Leroy ^a   Lea, Robert ^a   Shervington, Amal ^a  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

5azadC; Demethylation; Glioblastoma; MGMT; Telomerase

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PACLITAXEL; TAMOXIFEN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TEMOZOLOMIDE;

ARTICLE; BRAIN TISSUE; DEMETHYLATION; EPENDYMOMA; EPIGENETICS; GENE SILENCING; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BRAIN NEOPLASMS; CELL AGING; CELL LINE, TUMOR; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOMA; HUMANS; METHYLTRANSFERASES; PACLITAXEL; RNA, MESSENGER; TELOMERASE;

EID: 37449009206     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.10.043     Document Type: Article

References (34)

1. Auger N., Thillet J., Wanherdrick K., Idbaih A., Legrier M.E., Dutrillaux B., Sanson M., and Poupon M.F. Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. Mol. Cancer Ther. 5 (2006) 2182-2192
2. Bearzatto A., Szadkowski M., Macpherson P., Jiricny J., and Karran P. Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents. Cancer Res. 60 (2000) 3262-3270
3. Brandes A.A., Tosoni A., Basso U., Reni M., Valduga F., Monfardini S., Amistà P., Nicolardi L., Sotti G., and Ermani M. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J. Clin. Oncol. 22 (2004) 4779-4786
4. Christman J.K. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21 (2002) 5483-5495
5. Cohen M.H., Johnson J.R., and Pazdur R. Food and Drug Administration Drug Approval Summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin. Cancer Res. 11 (2005) 6767-6771
6. 6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. Mol. Cancer Ther. 4 (2005) 61-69
7. Dessain S.K., Yu H., Reddel R.R., Beijersbergen R.L., and Weinberg R.A. Methylation of the human telomerase gene CpG island. Cancer Res. 60 (2000) 537-541
8. Devereux T.R., Horikawa I., Colleen H.A., Annab L.A., Afshari C.A., and Barrett J.C. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res. 59 (1999) 6087-6090
9. Dong C.K., Masutomi K., and Hahn W.C. Telomerase: regulation, function and transformation. Crit. Rev. Oncol. Hematol. 54 (2005) 85-93
10. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., Baylin S.B., and Herman J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343 (2000) 1350-1354
11. Esteller M., Gaidano G., Goodman S.N., Zagonel V., Capello D., Botto B., Rossi D., Gloghini A., Vitolo U., Carbone A., Baylin S.B., Herman J.E., Baylin S.B., and Herman J.G. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 94 (2002) 26-32
12. Ganesh T., Guza R.C., Bane S., Ravindra R., Shanker N., Lakdawala A.S., Snyder J.P., Kingston D.G.I., and Meyers A.I. The bioactive taxol conformation on β-tubulin: experimental evidence from highly active constrained analogs. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10006-10011
13. Gore S.D., Baylin S., Sugar E., Carraway H., Miller C.B., Carducci M., Grever M., Galm O., Dauses T., Karp J.E., Rudek M.A., Zhao M., Smith B.D., Manning J., Jiemjit A., Dover G., Mays A., Zwiebel J., Murgo A., Weng L.J., and Herman J.G. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66 (2006) 6361-6369
14. Guilleret I., and Benhattar J. Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp. Cell Res. 289 (2003) 326-334
15. Guillermo G.M., Hagop M.K., and Blanca S.G. Phase I/II study of the combination of 5-aza-2′-deoxycytidine (DAC) with valproic acid (VPA) in patients with leukaemia. Blood 108 (2006) 3271-3279
16. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.E., Tribolet N.D., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E.C., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., and Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352 (2005) 997-1003
17. Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., Bayar E., Lyons J., Rosenfeld C.S., Cortes J., and Kantarjian H.M. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103 (2004) 1635-1640
18. Kanzawa T., Germano I.M., Kondo Y., Ito H., Kyo S., and Kondo S. Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br. J. Cancer 89 (2003) 922-929
19. Keith W.N., and Hoare S.F. Detection of telomerase hTERT gene expression and its splice variants by RT-PCR. Methods Mol. Med. 97 (2004) 297-309
20. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., and Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
21. Kitagawa Y., Kyo S., Takakura M., Kanaya T., Koshida K., Namiki M., and Inoue M. Demethylating reagent 5-azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of hTERT. Clin. Cancer Res. 6 (2000) 2868-2875
22. Kiyozuka Y. Correlation of telomerase activity and telomere length to chemosensitivity. Methods Mol. Med. 111 (2005) 97-108
23. + cancer stem cells in glioblastoma. Mol. Cancer 5 (2006) 67-79
24. Matsutomi K., Yu E.Y., Khurts S., Ben-Porath I., Currier J.L., Metz G.B., Brooks M.W., Kaneko S., Murakami S., DeCaprio J.A., Weinberg R.A., Stewart S.A., and Hahn W.C. Telomerase maintains telomere structure in normal human cells. Cell 114 (2003) 241-253
25. Nakamura M., Watanabe T., Yonekawa Y., Kleihues P., and Ohgaki H. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22 (2001) 1715-1719
26. Natsume A., Ishii D., Wakabayashi T., Tsuno T., Hatano H., Mizuno M., and Yoshida J. IFN-β down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 65 (2005) 7573-7579
27. Shervington A., Patel R., Lu C., Cruickshanks N., Lea R., Roberts G., Dawson T., and Shervington L. Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res. 1134 (2007) 45-52
28. Siddiqa A., Cavazos D.A., and Marciniak R.A. Targeting telomerase. Rejuvenation Res. 9 (2006) 378-390
29. Szyf M., Pakneshan P., and Rabbani S.A. DNA demethylation and cancer: therapeutic implications. Cancer Lett. 211 (2004) 133-143
30. Takakura M., Kyo S., Sowa Y., Wang Z., Yatabe N., Maida Y., Tanaka M., and Inoue M. Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res. 29 (2001) 3006-3011
31. Tentori L., Portarena I., Barbarino M., Balduzzi A., Levati L., Vergati M., Biroccio A., Gold B., Lombardi M.L., and Graziani G. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly(ADP-ribose) polymerase inhibitor. Mol. Pharmacol. 63 (2003) 192-202
32. van den Bent M.J., Hegi M.E., and Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur. J. Cancer 42 (2006) 582-588
33. Young J.I., Sedivy J.M., and Smith J.R. Telomerase expression in normal human fibroblasts stabilizes DNA 5-methylcytosine transferase I. J. Biol. Chem. 278 (2003) 19904-19908
34. Waha A., Güntner S., Huang T.H., Yan P.S., Arslan B., Pietsch T., Wiestler O.D., and Waha A. Epigenetic silencing of the rotocadherin family member PCDH-γ-A11 in astrocytomas. Neoplasia 7 (2005) 193-199